Medtide Inc.(03880.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
Medtide Inc.
03880.HK
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening.
817.24 B
03880.HKMarket value -Rank by Market Cap -/-

Financial Score

29/01/2026 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking7/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.46%B
    • Profit Margin22.19%A
    • Gross Margin61.06%A
  • Growth ScoreA
    • Revenue YoY34.45%A
    • Net Profit YoY46.83%B
    • Total Assets YoY67.84%A
    • Net Assets YoY387.40%A
  • Cash ScoreB
    • Cash Flow Margin450.74%C
    • OCF YoY34.45%A
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreA
    • Gearing Ratio17.08%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Medtide Inc. Announces Key Corporate Secretary Changes

    Medtide Inc. (HK:3880) announced changes in its corporate secretary roles, with Mr. Lee Chung Shing resigning and Mr. Ng Tung Ching Raphael appointed as his replacement, effective September 26, 2025. The company also secured a waiver from the Stock Exchange for Ms. Li Lingmei to remain as a joint company secretary. The latest analyst rating for Medtide's stock is a Hold, with a price target of HK$38.00.

    Tip Ranks·
    HK
    03880
    -2.50%
    Tip Ranks·
    HK
    03880
    -2.50%

    Medtide Inc.: Wu Dongcheng has been appointed as Co-Company Secretary

    Medtide Inc. announced that Mr. Li Zhongcheng will resign as Co-Company Secretary and other positions on September 26, 2025. Mr. Wu Dongcheng will succeed him as Co-Company Secretary, Authorized Representative, and Legal Process Agent. Ms. Li Lingmei will continue to serve as another Co-Company Secretary

    Zhitong·
    HK
    03880
    -2.50%
    Zhitong·
    HK
    03880
    -2.50%

    Medtide Inc. Reports 28.5% Rise in Revenue and 101.7% Increase in Net Profit for H1 2025

    Medtide Inc. reported a 28.5% increase in revenue for H1 2025, reaching RMB 253.8 million, and a 101.7% rise in net profit to RMB 102.0 million. The gross profit margin improved to 61.1%. The company completed its global offering and became listed in June 2025, funding operations through business activities and equity issuance. Medtide aims for sustainable growth in CRDMO services for peptides and oligonucleotides while managing liquidity for shareholder stability and returns.

    Reuters·
    HK
    03880
    -2.50%
    Reuters·
    HK
    03880
    -2.50%

    Medtide Inc. released its interim results, with shareholders' profit attributable to them reaching 102 million yuan, an increase of 101.71% year-on-year

    According to the Zhitong Finance APP, Medtide Inc. released its interim results for the six months ending June 30, 2025, with revenue of RMB 254 million, an increase of 28.52% year-on-year; profit attributable to shareholders of RMB 102 million, an increase of 101.71% year-on-year; and basic earnings per share of RMB 0.82. The announcement stated that the increase in revenue was mainly due to the rise in revenue from FFS and FTE businesses, driven by increased demand from clients for the group's services

    Zhitong·
    HK
    03880
    -2.50%
    Zhitong·
    HK
    03880
    -2.50%

    Medtide Inc. Reports 28.5% Increase in Revenue and 101.7% Surge in Net Profit for H1 2025

    Medtide Inc. reported a 28.5% increase in revenue to RMB 253.8 million and a 101.7% surge in net profit to RMB 102.0 million for H1 2025. Gross profit rose by 44.3% to RMB 155.0 million, with a gross profit margin of 61.1%. Revenue from the U.S. increased significantly, while revenue from Mainland China decreased. The company did not provide future outlook or guidance in this announcement.

    Reuters·
    HK
    03880
    -2.50%
    Reuters·
    HK
    03880
    -2.50%
    © 2026 Longbridge｜Disclaimer